6/20/2018
`
`ACHN ATCC ® CRL-1611 rM Homo sapiens kidney; derived from meta
`
`ACHN (ATCC®CRL-1611™)
`Organism:~~. human I Tissue: .!ill!ru!y; derived from metastatic site: pleural effusion Disease: renal cell adenocarcinoma
`SHARE I EMAIL : PRINT
`
`r;(~CUMENTATIOt,;
`
`Permits and Rostrlctlons
`
`Viow Permits
`
`Organism
`
`Tissue
`
`Homo sapiens, human
`
`kidney; derived from metastatic site: pleural effusion
`
`Product Format
`
`frozen
`
`Morphology
`
`epithelial
`
`Culture Properties
`
`adherent
`
`Blosafety Level
`
`Biosafety classification is based on US Public Health Service
`
`~ •. it Is the responsibility of the customer to ensure that
`
`their facilities comply with biosafety regulations for their own
`
`countiy
`
`Disease
`
`Ago
`
`Gender
`
`Ethnicity
`
`renal coll adenocarclnorna
`
`22 years
`
`male
`
`Caucasiar1
`
`Applications
`
`ACHN may be of use for antiproliforativo studies using human
`interferons or inte,ieron inducers.
`
`Storage Conditions
`
`liquid nitrogen vapor temperature
`
`https://www.atcc.org/Prod ucts/ AII/C R L-1611 . aspx? &p= 1 &rel =general information#general inform a lion
`
`1/1
`
`Breckenridge Exhibit 1158
`Breckenridge v. Novartis IPR2017-01592
`CRL-1611-ACHN
`Page 1
`
`
`
`ACHN ATCC ® CRL-1611 rM Homo sapiens kidney; derived from meta
`
`ACHN (ATCC®CRL-1611™)
`Organism:~~. human I Tissue: .!ill!ru!y; derived from metastatic site: pleural effusion Disease: renal cell adenocarcinoma
`SHARE I EMAIL : PRINT
`
`r;(~CUMENTATIOt,;
`
`Permits and Rostrlctlons
`
`Viow Permits
`
`Organism
`
`Tissue
`
`Homo sapiens, human
`
`kidney; derived from metastatic site: pleural effusion
`
`Product Format
`
`frozen
`
`Morphology
`
`epithelial
`
`Culture Properties
`
`adherent
`
`Blosafety Level
`
`Biosafety classification is based on US Public Health Service
`
`~ •. it Is the responsibility of the customer to ensure that
`
`their facilities comply with biosafety regulations for their own
`
`countiy
`
`Disease
`
`Ago
`
`Gender
`
`Ethnicity
`
`renal coll adenocarclnorna
`
`22 years
`
`male
`
`Caucasiar1
`
`Applications
`
`ACHN may be of use for antiproliforativo studies using human
`interferons or inte,ieron inducers.
`
`Storage Conditions
`
`liquid nitrogen vapor temperature
`
`https://www.atcc.org/Prod ucts/ AII/C R L-1611 . aspx? &p= 1 &rel =general information#general inform a lion
`
`1/1
`
`Breckenridge Exhibit 1158
`Breckenridge v. Novartis IPR2017-01592
`CRL-1611-ACHN
`Page 1
`
`
`
`6/20/2018
`
`ACHN ATCC ® CRL-1611 ™ Homo sapiens kidney; derived from meta
`
`ACHN (ATCC®CRL-1611™ )
`Organism: f:t.Qm.Q._fil/~,_rumi;in I lissue: kidney; derived from metastatic site: pleural effusion Disease: renal cell adenocarclnoma
`
`SHARE EMAIL PRINT
`
`Derivation
`
`Th0 ACHN cell line was initiated in Novombor. 1979 from tho
`
`malignant pleural effusion of a 22-year-old Caucasian male with
`
`widely metastatic renal adenocarcinoma (autopsy confirmed).
`
`Cells were seeded directly to culture flasks In Eagle's MEM with
`10% FBS, thon maintained and passaged 150 days in flasks.
`Cells were then inoculated subcutaneously into nude mice. After
`
`4 weeks, palpable, locally invasive tumors were noted. Both the
`
`original cells (ACHN) and those recovered from nude mouse
`tumors were growlh-lnt,lbiled by human Interferons.
`
`Clinical Data
`
`22 years
`Caucasian
`male
`
`Tumorlgenlc
`
`Yes
`
`Effects
`
`Comments
`
`Yes, in nudo mice
`(Tumors developed within 21 days at 100% frequency (5/5) in
`nude mice Inoculated subcutaneously with 10(7) cells)
`
`Growth Is Inhibited by human interferon [Hogan, T. F., personal
`communication].
`
`https://www.atcc.org/Products/AII/CRL-1611.aspx?&p=1 &rel=characteristics#characteristics
`
`1/1
`
`Breckenridge Exhibit 1158
`Breckenridge v. Novartis IPR2017-01592
`CRL-1611-ACHN
`Page 2
`
`
`
`6/20/2018
`
`ACHN ATCC ® CRL-1611 ™ Homo sapiens kidney; derived from meta
`
`ACHN (ATCC® CRL-1611 ™)
`Organism: ~piens,.lli!!lliill I Tissue: .!ill!.ru!y: derived from metastatic site: pleural effusion Disease: renal cell adenocarcinoma
`
`SHARE EMAIL PRINT
`
`Complota Growth Medium
`
`Tho base medium for this coll lino is Al'CC-formulatod Eagle's
`Minimum Essential Medium, Catalog No. 30-2003. To make the
`complete growth medium, add the following components to the
`base medium: fetal bovine serum to a final concentration of 10%.
`
`Subculturing
`
`Volumes are given for a 75 cm 2 flask. Increase or decrease t11e
`amount of dissociation medium needed proportionally for culture
`vessels of other sizes.
`1. Remove and discard culture medium.
`
`2. Briefly rinse the cell layer wit11 0.25% (w/v) Trypsin - 0.53 mM
`EOTA solution to remove all traces of serum which contains
`trypsin inhibitor.
`
`3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and
`observe cells under an Inverted microscope until cell layer Is
`dispersed (usually within 5 to 15 minutes).
`Note: To avoid clumping do not agitate the cells by hitting or
`shaking tho flask while waiting for the cells to detach. Cells
`that are difficult to detach may be placed at 37°C to facilitate
`dispersal.
`
`4. Add 6.0 to 8.0 ml of complete growth medium and aspirate
`cells by gently pipetting.
`
`5. Add appropriate aliquots of the cell suspension to new culture
`vessels.
`
`6. Incubate cultures at 37°C.
`
`Subcultivatlon Ratio: A subcultivation ratio of 1 :2 to 1 :3 is
`recommended
`Medium Renewal: 2 to 3 times per weak
`
`Cryopreservatlon
`
`Freeze medium: Complete growth medium, 95%; DMSO, 5%
`Storage temperature: liquid nitrogen vapor temperature
`
`Culture Conditions
`
`Atmosphere: air, 95%; carbon dioxide (CO2), 5%
`Temperature: 37°C
`
`https://www.atcc.org/Products/AII/CRL-1611 .aspx?&p= 1 &rel=culturemethod#culturemethod
`
`1/1
`
`Breckenridge Exhibit 1158
`Breckenridge v. Novartis IPR2017-01592
`CRL-1611-ACHN
`Page 3
`
`
`
`6/20/2018
`
`ACHN ATCC ® CRL-1611 TM Homo sapiens kidney; derived from meta
`
`ACHN (ATCC®CRL-1611™)
`Organism: ~,mm§ • ..h.\unrul I Tissue: .!IB!ruly; derived from metastatic site: pleural effusion / Disease: renal cell adenocarclnoma
`
`SHARE EMAIL
`
`
`STR Profile
`
`Am0log0nin: X
`CSF1PO: 11
`DBS317: 12
`O16S539: 12,13
`O5S818: 12
`O7S820: 9,11
`THO1: 8
`TPOX: 8,11
`vWA: 16,17
`
`lsoenzymes
`
`G6PD, B
`
`https://www.atcc.org/Products/AII/CRL- 1611.aspx?&p=1 &rel=specifications#specifications
`
`1/1
`
`Breckenridge Exhibit 1158
`Breckenridge v. Novartis IPR2017-01592
`CRL-1611-ACHN
`Page 4
`
`
`
`6/20/2018
`
`ACHN ATCC ® CRL-1611 TM Homo sapiens kidney; derived from meta
`
`ACHN (ATCC® CRL-1611™)
`Organism: Homo sapifil!li,..ill!l!lM. I llssue: kidru!Y.; derived from metastatic site: pleural effusion I Disease: renal cell adenocarcinoma
`
`HISTORY
`
`l':CCUMl:NTATICN
`
`SHARE EMAIL PRINT
`
`Name of Doposltor
`
`TF Hogan
`
`Deposltod As
`
`1-/omo sopiens
`
`Year of Origin
`
`November, 1979
`
`References
`
`Tumors developed within 21 d/Jys at 100% frequ0nc:y (5/5) In
`
`nude mice inoculated subcutanoousty with 10(7) col ts
`
`The ACHN cell tine was initiated In November, 1979 from the
`
`mallgnant pleural effusion of a 22-year-old Caucasian malo with
`
`widely metastatic renal adenocarcinoma (autopsy confirmed).
`
`Cells were seeded directly to culture flasks in Eagle's MEM with
`
`10% FBS, then maintained and passaged 150 days In flasks.
`
`Cells wero then inoculated subcutanoously into nude mice. After
`
`4 weeks, palpable, locally invasive tumors were noted. Both the
`
`original cells (ACHN) and those recovered from nude mouse
`
`tumors were growth-Inhibited by human Interferons.
`
`Kocl1evar J. Blockage of autonomous growth of ACHN cells by
`
`anti-renal cell carcinoma monoclonal antibody 5F4. Cancer Res.
`20: 2968-2972, 1990. PubMed: 2334900
`
`https://www.atcc.org/Products/AII/CRL-1611.aspx?&p=1 &rel=history#hlstory
`
`1/1
`
`Breckenridge Exhibit 1158
`Breckenridge v. Novartis IPR2017-01592
`CRL-1611-ACHN
`Page 5
`
`
`
`6/20/2018
`
`ACHN ATCC ® CRL-1611 TM Homo sapiens kidney; derived from meta
`
`ACHN (ATCC®CRL-1611™)
`Organism: HQmQ.fil!~,l:!.!.!rr!J!.n / lissue: .!ill!.!:!.!!y; derived from metastatic site: pleural effusion Disease: renal cell adenocarclnoma
`
`SHARE EMAIL i PRINT
`
`Permits
`
`These permits may be required for shipping this product:
`
`Customers loc:atod In tho state) of Hawaii will neod to contact
`the Hawaii Department of Agriculture to determine if an Import
`Permit Is required. A copy of the permit or documentat1011 that
`a pormit is not roquired must bo sent to Al'CC in advance of
`shipment.
`
`Basic Documentation
`
`Product Sheet Certificate of AnalY.sls
`
`SOS
`
`References
`
`Tumors developed wit11in 21 days at 100% frequency (5/5) in
`
`nudu mice inoculated subcutaneously with 10(7) cells
`
`T11e ACHN cell line was initiated In November, 1979 from the
`
`malignant pleural effusion of a 22-year-old Caucasian male with
`
`widely metastatic renal adonocarcinoma (autopsy confirmed).
`
`Cells were seeded directly to culture flasks in Eagle's MEM with
`
`10% FBS, then maintained and passaged 150 days 111 flasks.
`
`Cells were then Inoculated subcutaneously into nude rnlce. After
`
`4 weeks, palpable, locally invasive tumors were noted. Both tho
`
`original cells (ACHN) and those recovered from nude mouse
`
`tumors were growth-inhibited by l1uman inte1fero11s.
`
`Kochevar J. Blockage of autonomous growth of ACHN cells by
`anti-renal cell carcinoma monoclonal antibody 5F 4. Cancer Res.
`
`20: 2968-2972, 1990. PubMed: 2334900
`
`https://www.atcc.org/Products/AII/CRL-1611.aspx?&p=1 &rel=documentation#documentation
`
`1/1
`
`Breckenridge Exhibit 1158
`Breckenridge v. Novartis IPR2017-01592
`CRL-1611-ACHN
`Page 6
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
